How I manage patients with acquired haemophilia A.
Acquired haemophilia A (AHA) is a potentially life-threatening bleeding disorder occurring in patients without a previous personal or family history of bleeding. Development of immune-mediated autoantibodies against coagulation factor VIII is associated with a wide range of clinical disorders including pregnancy, autoimmune disorders, malignancy, or with no apparent disease. There exists great potential for morbidity and mortality related to acute and recurrent bleeding episodes, making prompt diagnosis and treatment necessary. The two primary goals of treatment focus on cessation of bleeding and eradication of the acquired factor VIII inhibitor. No randomized clinical trials have been conducted regarding treatment, so expert clinical opinion guides therapeutic intervention. This current report provides a profile of patient characteristics, an algorithm for diagnosis, and outlines treatment recommendations based upon current guidelines and clinical experience. As first-line interventions for acute bleeding and inhibitor eradication are generally accepted, we will emphasize discussion of second-line therapeutic options.
Division of Hematology and Oncology, Ohio State University Medical Center, The Arthur G. James Comprehensive Cancer Center, Columbus, OH, USA. douglas.sborov@osumc.edu
Douglas W
DW
Sborov
George M
GM
Rodgers
D000465:Algorithms; D001323:Autoantibodies / Q000097:blood / Q000276:immunology; D019774:Blood Coagulation Factor Inhibitors / Q000097:blood / Q000276:immunology; D005260:Female; D006467:Hemophilia A / Q000097:blood / Q000175:diagnosis / Q000276:immunology / Q000628:therapy; D006801:Humans; D008297:Male; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000097:blood / Q000175:diagnosis / Q000276:immunology / Q000628:therapy
D001323:Autoantibodies; D019774:Blood Coagulation Factor Inhibitors